RenovoRx

RNXT

Biotechnology · Healthcare

Price

$1.12

-0.03 (-2.61%)

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 9, 2026 · filings through Mar 31, 2026

RenovoRx is a small biotech company focused on developing treatments for cancer. Its main product candidate is REM-001, a drug-device combination therapy designed to deliver chemotherapy directly to pancreatic tumors through a specialized catheter system. The company targets patients with locally advanced pancreatic cancer, one of the hardest cancers to treat, and its customers are hospitals and oncology clinics.

RenovoRx earns no meaningful revenue yet — it is a clinical-stage company spending money on research and trials rather than selling products. It operates primarily in the United States and has a very small market capitalization, meaning it relies on outside funding to keep running. The key growth driver is advancing REM-001 through clinical trials and eventually gaining FDA approval, but the main risk is that the company could run out of cash before reaching that milestone, which is a common and serious challenge for early-stage biotechs.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+185.8% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

-20.1% YoY

YoY Growth Rate

Earnings declining

Insider Activity

0.0%ownership

Relatively low insider ownership

Cash Runway

~10 months

$12M cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Strong grower

RenovoRx is growing revenue at 186% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

85.1%

Premium pricing power — 85.1% gross margin

Operating Margin

-616.2%

Losing money on operations — -616.2%

ROCE

-30.6%

Weak — -30.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+520.4%

Fast-growing sales (+520.4% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-759.0%

Burning cash (-759.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial